Thyrocare Technologies Limited

NSE THYROCARE.NS

Thyrocare Technologies Limited EBITDA Margin for the year ending March 31, 2024: 25.90%

Thyrocare Technologies Limited EBITDA Margin is 25.90% for the year ending March 31, 2024, a 4.18% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Thyrocare Technologies Limited EBITDA Margin for the year ending March 31, 2023 was 24.86%, a -44.57% change year over year.
Thyrocare Technologies Limited EBITDA Margin for the year ending March 31, 2022 was 44.86%, a 20.78% change year over year.
Thyrocare Technologies Limited EBITDA Margin for the year ending March 31, 2021 was 37.14%, a -7.36% change year over year.
Thyrocare Technologies Limited EBITDA Margin for the year ending March 31, 2020 was 40.09%, a -2.02% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NSE: THYROCARE.NS

Thyrocare Technologies Limited

CEO	Mr. Rahul Franklin Guha
IPO Date	May 10, 2016
Location	India
Headquarters	D/37-3, TTC Industrial Area
Employees	1,693
Sector	Health Care
Industries Pharmaceuticals Hospitals & Clinics Telehealth

Description

Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates in three segments: Diagnostic Testing Services, Imaging Services, and Others. The company conducts various medical diagnostic tests and profiles of tests that focuses on early detection and management of disorders and diseases, including thyroid, growth, metabolism, auto-immunity, diabetes, anaemia, cardiovascular, infertility, COVID, and various infectious diseases. Its profiles of tests include 34 profiles of tests administered under its Aarogyam brand, which offers patients a suite of wellness and preventive health care tests. The company also sells glucometer and glucostrips under the brand name Sugarscan; consumables; and radiopharmaceutical. Thyrocare Technologies Limited was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited.

Key trends

Past 5 years